499 research outputs found

    Research Journal of Pharmaceutical, Biological and Chemical Sciences ANTIOXIDANT AND ANTIHYPERGLYCEMIC POTENTIAL OF METHANOLIC EXTRACT OF BARK OF MIMUSOPS ELENGI L. IN MICE

    Get PDF
    ABSTRACT Ayurveda refers Mimusops elengi L. for the treatment of the diabetes. Considering the traditional claim of M. elengi in management of diabetes and the possible involvement of oxidative stress in pathogenesis of diabetes, the present study was aimed to evaluate the in vitro antioxidant and in vivo antihyperglycemic property of methanolic extract of bark of M. elengi (MEMeOH). In vitro antioxidant activity of MEMeOH was evaluated using reducing power assay, DPPH and hydroxyl radical scavenging assay. MEMeOH offered significant in vitro reducing power capacity and radical scavenging activity. In acute study in alloxan induced diabetes, MEMeOH exhibited significant (p< 0.001) antihyperglycemic effect. The onset of antihyperglycemic effect was observed at 2 nd hr; peak activity was demonstrated at 6 th hr. The antihyperglycemic effect of MEMeOH 400mg/kg, p.o. was persistent up to 24 th hr after drug administration. MEMeOH produced significant (p < 0.01) reduction in elevated glucose levels in glucose loaded non diabetic animals. The onset of action in non diabetic oral glucose tolerance test was found to be at 60 th min and peak activity was observed at 120 th min after oral glucose load. MEMeOH demonstrated significant (p < 0.01) reduction in elevated glucose levels 2hr before glucose administration and 6 hr after glucose load in oral glucose tolerance test in diabetic animals. MEMeOH has demonstrated antihyperglycemic activity in diabetic as well as non diabetic glucose loaded mice. MEMeOH should be further explored against diabetes and related complications

    Ptch2/Gas1 and Ptch1/Boc differentially regulate Hedgehog signalling in murine primordial germ cell migration.

    Get PDF
    Gas1 and Boc/Cdon act as co-receptors in the vertebrate Hedgehog signalling pathway, but the nature of their interaction with the primary Ptch1/2 receptors remains unclear. Here we demonstrate, using primordial germ cell migration in mouse as a developmental model, that specific hetero-complexes of Ptch2/Gas1 and Ptch1/Boc mediate the process of Smo de-repression with different kinetics, through distinct modes of Hedgehog ligand reception. Moreover, Ptch2-mediated Hedgehog signalling induces the phosphorylation of Creb and Src proteins in parallel to Gli induction, identifying a previously unknown Ptch2-specific signal pathway. We propose that although Ptch1 and Ptch2 functionally overlap in the sequestration of Smo, the spatiotemporal expression of Boc and Gas1 may determine the outcome of Hedgehog signalling through compartmentalisation and modulation of Smo-downstream signalling. Our study identifies the existence of a divergent Hedgehog signal pathway mediated by Ptch2 and provides a mechanism for differential interpretation of Hedgehog signalling in the germ cell niche

    Inflation and dark matter in two Higgs doublet models

    Get PDF
    We consider the Higgs inflation in the extension of the Standard Model with two Higgs doublets coupled to gravity non-minimally. In the presence of an approximate global U(1) symmetry in the Higgs sector, both radial and angular modes of neutral Higgs bosons drive inflation where large non-Gaussianity is possible from appropriate initial conditions on the angular mode. We also discuss the case with single-field inflation for which the U(1) symmetry is broken to a Z_2 subgroup. We show that inflationary constraints, perturbativity and stability conditions restrict the parameter space of the Higgs quartic couplings at low energy in both multi- and single-field cases. Focusing on the inert doublet models where Z_2 symmetry remains unbroken at low energy, we show that the extra neutral Higgs boson can be a dark matter candidate consistent with the inflationary constraints. The doublet dark matter is always heavy in multi-field inflation while it can be light due to the suppression of the co-annihilation in single-field inflation. The implication of the extra quartic couplings on the vacuum stability bound is also discussed in the light of the recent LHC limits on the Higgs mass.Comment: (v1) 28 pages, 8 figures; (v2) 29 pages, a new subsection 3.3 added, references added and typos corrected, to appear in Journal of High Energy Physic

    Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Little data exist on how opioid doses vary with the length of exposure among chronic opioid users.</p> <p>Methods</p> <p>To characterize the change in the dosage of opioids over time, a retrospective cohort study using the PharMetrics database for the years 1999 through 2008 was conducted. Individuals exposed to opioids in 2000 who had 2 opioid dispensings at least 6 months apart and were opioid naive (did not receive any opioid 6 month before their exposure in 2000) were included. The date of the first dispensing in 2000 was defined as the index date and the dispensing had to be for a strong and full agonist opioid. All opioid doses were converted to oral morphine equivalent doses. Exposure was classified as continuous or intermittent. Mean, median, interquartile range, and 95<sup>th </sup>percentile of opioid dose over 6-month periods, as well as the percentage of subjects who ever received a high or very high opioid dose, were calculated.</p> <p>Results</p> <p>Among the 48,986 subjects, the mean age was 44.5 years and 54.5% were women. Intermittent exposure was observed in 99% of subjects; continuous exposure was observed in 1% of subjects. The mean duration of exposure for the subjects who were continuously exposed to opioids was 477 days. In subjects with no cancer diagnosis who were continuously exposed to opioids, the mean, 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th </sup>percentile of dose was stable during the first 2 years of use, but the 95<sup>th </sup>percentile increased. Seven percent of them were exposed to doses of 180 mg or more of morphine at some point.</p> <p>Conclusions</p> <p>Dose escalation is uncommon in subjects with intermittent exposure to opioids. For subjects with continuous exposure to opioids who have cancer, doses rise substantially with time. For those without cancer, doses remain relatively stable for the first 2 years of use, but subsequently increase. Seven percent of subjects with no cancer diagnosis will be exposed to daily doses of 180 mg or more of morphine equivalent at some point.</p
    • …
    corecore